Trial Profile

A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Sep 2012 Results from a pooled analysis of GLOW 1 and GLOW 2 presented at the 22nd Annual Congress of the European Respiratory Society.
03 Sep 2012 Results from pooled analyses of GLOW-1 and GLOW-2 have been presented at the 2012 Annual Congress of the European Society of Cardiology (ESC-2012) according to a Novartis media release. Results were also summarised in the media release.
26 Jul 2012 Additional trial locations added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com